What If the War Is Already Over?

The Gap Between What Precision Oncology Can Do and What Most Patients Actually Get

In 1974, a Japanese intelligence officer named Hiroo Onoda walked out of the Philippine jungle on Lubang Island. He had been fighting World War II for 29 years after it ended. Leaflets had been dropped. Newspapers were left on trails. His own family wrote letters pleading with him to come home. He dismissed all of it as enemy propaganda. His companions died one by one. He kept fighting.

He only surrendered when his former commanding officer, Major Yoshimi Taniguchi, flew from Japan to the island and formally relieved him of duty. The information had been available for decades. What was missing was a channel he trusted to deliver it.

Cancer patients are living a version of this story right now.

The war against their specific mutation may already have a weapon. The therapy may already exist, FDA-approved or in a late-stage trial. But no one sequenced their tumor. Or the sequencing was done but the results were never acted on. Or the oncologist saw the results but defaulted to guidelines written for the average patient, not the patient in the chair.

The information is there. The channel is broken.

The Weapons on the Shelf

The NCI-MATCH trial, published by Flaherty, Salama, and colleagues in the Journal of Clinical Oncology in 2020, screened patients with refractory solid tumors and found actionable alterations in 37.6 percent of those tested. Nearly two in five. The AACR Project GENIE consortium, one of the largest public cancer genomic datasets in the world, has confirmed that more than 30 percent of sequenced tumors carry at least one actionable mutation matchable to an existing targeted therapy. For specific cancer types, the numbers are higher still. In non-small cell lung cancer, studies have identified actionable oncogenic drivers in up to 69 percent of patients, including EGFR mutations, ALK rearrangements, KRAS G12C mutations, and half a dozen others.

Next-generation sequencing panels can now profile hundreds of genes from a single biopsy. Platforms like FoundationOne CDx, Tempus xT, and Caris Molecular Intelligence identify mutations, fusions, and amplifications that predict drug response. A decade ago, this was research infrastructure. Today it is a clinical product, available in any oncology practice willing to order it. The question is no longer whether but how often.

When patients with actionable mutations receive the matched drug, the outcomes are not marginal improvements. They are categorical shifts. In ALK-positive non-small cell lung cancer, the CROWN trial reported five-year progression-free survival of 60 percent with lorlatinib, published by Solomon and colleagues in the Journal of Clinical Oncology in 2024. Sixty percent of patients with metastatic lung cancer still alive and progression-free at five years. That number would have been inconceivable a decade ago. It required two things: a drug designed for the target, and a test to find the target.

In HER2-low breast cancer, trastuzumab deruxtecan produced responses in patients previously classified as HER2-negative, a population once considered ineligible for HER2-targeted therapy. The DESTINY-Breast04 trial, led by Modi and published in the New England Journal of Medicine in 2022, redrew the boundary of who benefits. But it only works if the HER2 status is characterized precisely enough to identify the "low" expression that the old binary classification missed entirely.

Across tumor types, larotrectinib works in salivary gland tumors, thyroid cancers, sarcomas, and infantile fibrosarcomas alike. Dabrafenib plus trametinib has demonstrated activity in BRAF V600E-mutated cancers regardless of the organ of origin. The mutation is the indication. The organ is incidental.

These are not experimental therapies stuck in Phase 1 trials. They are FDA-approved, commercially available, and supported by randomized evidence. The weapons exist. They are on the shelf.

My Own Last Battle

I know what it means to fight a cancer with the wrong weapon, because I nearly did.

My cancer is AL amyloidosis, a rare and aggressive variant of multiple myeloma in which malignant plasma cells produce misfolded light chain proteins that deposit in organs and destroy them. The standard approach to myeloma, and by extension amyloidosis, is a combination regimen designed for the broad population of myeloma patients. Without molecular subtyping, that is what I would have received.

But my tumor carries a t(11;14) translocation, a specific chromosomal rearrangement that drives overexpression of cyclin D1, a protein that accelerates cell division and should not be overproduced. That translocation has a second, more consequential implication: t(11;14) myeloma cells are uniquely dependent on a protein called BCL-2 that prevents the cell from self-destructing. Venetoclax, a drug designed to inhibit BCL-2, exploits that dependency with surgical precision. It removes the single load-bearing support, and the cell's intrinsic death machinery resumes function.

The BELLINI trial, published by Kumar et al. in The Lancet Oncology in 2020, tested venetoclax in relapsed myeloma. The overall trial showed excess mortality in the venetoclax arm, a finding that halted development in unselected myeloma. But the prespecified subgroup analysis of t(11;14) patients showed dramatically deeper responses and longer progression-free survival. The biology explained the divergence completely. Venetoclax works when BCL-2 is the dominant survival protein. In t(11;14) disease, it is. In other subtypes, different survival proteins may dominate instead, leaving the primary mechanism untouched.

Without cytogenetics, without the test that identified my translocation, I would have been treated with standard myeloma therapy. It would have been reasonable, guideline-concordant, and suboptimal for my specific disease. The weapon that matched my biology was on the shelf. The only question was whether anyone would look for the lock it fit.

The Testing Gap

If actionable mutations are present in 30 to 40 percent of tumors, fewer than half of patients with the most-tested cancer type receive all recommended biomarker tests.

Non-small cell lung cancer has more guideline-recommended biomarker tests than any other solid tumor. NCCN guidelines specify testing for EGFR, ALK, ROS1, BRAF, KRAS, RET, MET, NTRK, PD-L1, and HER2 before initiating first-line therapy. And yet, in a real-world study of the US Oncology Network published in Lung Cancer in 2022, fewer than 50 percent of patients with metastatic NSCLC received all recommended biomarker tests prior to first-line treatment. The MYLUNG pragmatic study, presented at ASCO 2023 by Evangelist, Butrynski, and colleagues, confirmed the pattern. Testing rates have improved over time, but the gap between guideline recommendation and clinical practice remains wide.

NSCLC is the best case. For most other solid tumors, comprehensive genomic profiling rates are far lower. Pancreatic cancer, ovarian cancer, sarcomas, biliary tract cancers: actionable targets exist, but no established culture of routine sequencing does. In those diseases, the testing gap is not a crack. It is a chasm.

Geography amplifies the problem. Approximately 80 to 85 percent of cancer patients in the United States are treated in community oncology practices, not academic medical centers. Community practices have lower sequencing rates, fewer molecular tumor boards, and less familiarity with the rapidly expanding landscape of targeted therapies. Where a patient lives and which oncologist they see determines whether their tumor gets read.

The Action Gap

Testing alone does not close the loop. Even when genomic profiling is performed, the results often fail to reach the treatment plan.

A study published in BMC Cancer in 2017 by Haslem and colleagues found that comprehensive genomic profiling revealed genomic alterations in 92 percent of patients with advanced cancer, making them candidates for genotype-directed therapy via on-label, off-label, or clinical trial options. Fifteen of 125 patients, 12 percent, actually received matched therapy. Three patients, 2 percent, derived measurable benefit.

Ninety-two percent had options on paper. Two percent benefited. The barriers were multiple: results arrived too late, the oncologist did not know how to interpret the report, insurance denied the matched drug, no clinical trial was available within driving distance.

Timing, in particular, determines everything. A study published in JCO Precision Oncology in 2024 showed that in advanced NSCLC, having sequencing results available before first-line treatment was associated with dramatically higher use of precision therapies. Matched targeted therapy use increased by 14 percentage points: 17 percent with timely results versus 2.8 percent with delayed results. The same patients, the same test, but results arriving before versus after the first treatment decision. My own sequencing results arrived early enough to change the plan. For most patients, that timing is a matter of luck, not system design.

The largest real-world analysis to date, published in Nature Medicine in January 2026, analyzed clinical and genomic data from tens of thousands of patients with advanced solid tumors who underwent comprehensive genomic profiling through Japan's national C-CAT system. The findings reinforced what smaller studies had shown: actionable alterations are common, but the pathway from identification to matched treatment is riddled with leaks. Transition rates varied dramatically by institution, geography, and tumor type. Leaflets are being dropped into the jungle, but no one trusts the channel.

Why the Gap Persists

Guidelines are population-level tools. NCCN guidelines represent the best treatment for the average patient. They are not designed to optimize for individual molecular profiles. Following guidelines is safe, defensible, and standard. Deviating from them requires knowledge, institutional support, and a willingness to absorb personal risk. An oncologist who prescribes an off-label drug based on a molecular rationale takes on liability that an oncologist following standard protocol does not. The malpractice exposure is real. If the off-label therapy causes harm, the oncologist has no guideline to point to in court. The patient may face catastrophic out-of-pocket costs if insurance refuses to cover a non-indicated use. The incentives favor the default, and not always irrationally.

Reimbursement compounds the problem. Ordering a $3,000 to $5,000 sequencing panel that might lead to an off-label insurance fight is less attractive than prescribing the standard regimen that gets approved in minutes. A community oncologist running a practice with thin margins does not get paid more for spending an extra hour interpreting a genomic report and building a case for targeted therapy.

Then there is time. Academic centers address complex genomic cases through molecular tumor boards, multidisciplinary committees that review cases weekly. Community practices rarely have that infrastructure. I was fortunate to be treated at an academic center with the resources to interpret my genomic report and act on it. Most cancer patients are not. The result is a two-tier system in which the depth of molecular interpretation depends on where the patient happens to be treated.

The information exists. The patient does not know to ask for it. The doctor may not have time to find it. The system does not connect the two.

And the gap is widening. New therapies arrive faster than clinical practice can absorb them. The FDA approved 55 novel drugs in 2023, including 13 novel oncology therapies, many with molecular biomarker requirements. Tumor-agnostic approvals compound the challenge: drugs like larotrectinib for NTRK fusions, pembrolizumab for tumors with high microsatellite instability or high tumor mutational burden (MSI-H/TMB-H), cancers carrying widespread DNA damage patterns that make them visible to the immune system, and dabrafenib plus trametinib for BRAF V600E mutations work across cancer types, but they require the mutation to be identified first. If no one sequences the tumor, the agnostic drug might as well not exist. AI is accelerating discovery on the research side. New targets, new combinations, new biomarker-response correlations are published weekly. The knowledge base expands exponentially. Clinical practice updates linearly. The distance between the frontier of what is known and the standard of what is practiced grows every month.

This creates the last-battle problem. Every month a patient spends on guideline-standard therapy while their tumor harbors an actionable mutation is a month of suboptimal treatment. For aggressive cancers, those months are not recoverable. The tumor evolves under the selective pressure of a therapy that does not match its biology, and that evolution can generate resistance to the targeted drug that would have worked if given first.

This is dying in the last battle of a war that is already over.

What Precision Oncology Cannot Do (Yet)

The argument for precision oncology is strong. Intellectual honesty requires acknowledging where it falls short.

Not all mutations are actionable. A tumor may harbor dozens of mutations, most of which are passengers, not drivers. Determining which mutations actually drive the cancer remains complex. Many patients receive genomic reports listing alterations for which no matched therapy exists.

Matched therapy does not always work. The NCI-MATCH trial, despite identifying actionable alterations in 37.6 percent of patients, showed modest overall response rates in many of its treatment arms. Molecular matching improves the odds. It does not guarantee the outcome. Tumor heterogeneity, co-occurring mutations, and microenvironmental factors (signals from neighboring cells and the surrounding tissue that can shield a tumor or alter drug delivery) all modulate whether a targeted drug delivers on its mechanistic promise.

Access remains unequal. Comprehensive genomic profiling costs roughly $3,000 to $5,000. Insurance coverage is inconsistent. Even when testing is covered, the matched therapy may require prior authorization battles and appeals. Patients without financial resources, health literacy, or a willing oncologist face barriers that molecular biology alone cannot solve.

There is also a legitimate health-economics question about universal sequencing. Testing every cancer patient in the United States would cost billions annually. Not every test will reveal an actionable target, and not every actionable target will have an accessible matched therapy. The counterargument is that a single line of ineffective chemotherapy costs far more than a $5,000 sequencing panel, and that identifying even one matched therapy earlier can eliminate months of futile treatment, reduce hospitalizations, and extend productive life. Haslem and colleagues published a separate analysis in JCO in 2018 estimating that CGP-guided therapy was associated with lower total cost of care compared to unmatched therapy. The math favors sequencing, but the upfront cost is real, and health systems operating on fixed budgets must weigh it against competing priorities.

These limitations are real. They do not, however, diminish the central argument. The gap between what is possible and what is delivered is not primarily a gap of science. It is a gap of implementation. The tools exist. The drugs exist. The evidence exists. The delivery system has not caught up.

What You Can Do

For any patient or caregiver navigating this landscape, the implications are concrete and actionable.

Get sequenced. At minimum, request comprehensive genomic profiling through a validated platform: FoundationOne CDx, Tempus xT, or Caris Molecular Intelligence. These panels profile hundreds of genes and identify mutations, fusions, and amplifications that may match approved therapies or open clinical trials. Ask your oncologist specifically: "Has my tumor been profiled for all known actionable mutations?" If the answer is no, ask why not.

Get sequenced early. The JCO Precision Oncology data could not be clearer: having results available before the first treatment decision is associated with dramatically higher rates of matched therapy use. After three lines of treatment have failed is not the time to discover that the tumor had an actionable mutation all along. Every week on the wrong regimen is a week the tumor uses to evolve resistance.

Understand your results. Feed the genomic report into AI tools: ChatGPT, Claude, CureWise. Ask which mutations have approved drugs. Ask which have active clinical trials. Ask what would change if this mutation were targeted. AI will not replace clinical judgment. A critical caveat: large language models can hallucinate, generating plausible but fabricated drug names, trial identifiers, or gene-drug associations. Every AI-generated claim must be verified against published sources before acting on it. AI surfaces connections that no single human, however expert, can reliably make across the full breadth of published literature. The connection between my t(11;14) translocation and venetoclax sensitivity was visible to anyone who read the BELLINI subgroup data. CureWise found it within minutes of being given my cytogenetics report. Use AI as a research accelerator, not as a clinician.

Find a molecular tumor board. Academic cancer centers hold weekly molecular tumor boards where genomic cases are reviewed by a multidisciplinary team: oncologists, pathologists, geneticists, and pharmacologists. Many NCI-designated cancer centers offer remote tumor board review or virtual second opinions. A community oncologist may not have the infrastructure to interpret a complex genomic report. A molecular tumor board does.

Search for trials. ClinicalTrials.gov remains the definitive registry. CureWise uses large language models to match patient profiles to eligible trials. A mutation with no approved drug today may have a Phase 2 trial enrolling right now.

Do not accept "it will not change management" without pushback. That statement may have been true five years ago for many cancers. The landscape is changing quarterly. When I was diagnosed, venetoclax was not approved for myeloma. The BELLINI trial data were available. The mechanism was understood. The drug was accessible off-label to any oncologist willing to prescribe it. "It will not change management" is a statement about the speaker's knowledge, not about the patient's biology.

The War Is Already Over (For Some)

Onoda lost 29 years fighting a war that was over. His tragedy was not stubbornness. It was information failure. The world had moved on. He had not been told in a way he could hear.

For a growing number of cancers, the war against a specific mutation already has an answer: a drug, a trial, a mechanism that works. The tragedy is not that the answer does not exist. It is that most patients never learn it does.

The balance here is not between hope and false hope. It is between informed action and uninformed default. Guideline-based care is not wrong. It is incomplete. It is the best answer for the average patient. Every patient deserves to know: am I average?

My t(11;14) translocation made me non-average in a way that changed everything. Without the test, I would have received a reasonable regimen designed for the average patient. The difference between that path and the one I am on is the distance this entire post is about.

Roughly one in three cancer patients has a tumor with an actionable mutation. Fewer than half of even the best-tested cancer type receive all recommended biomarker tests. When testing is done, the results frequently arrive too late, go uninterpreted, or fail to reach the treatment plan. The weapons are on the shelf. The patients are in the jungle.

The worst version of this story is the patient who discovers, after years of standard treatment, that their tumor had an actionable mutation all along. That a drug existed. That a trial was enrolling. That the weapon was right there, waiting, while they fought with what they had.

The war may already be over for your cancer. The question is whether anyone has told you.

---

References

1. Flaherty KT, Gray RJ, Chen AP, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: NCI-MATCH. Journal of Clinical Oncology. 2020;38(33):3883-3894. DOI: 10.1200/JCO.19.03010.

2. AACR Project GENIE Consortium. AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831.

3. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC (FLAURA). New England Journal of Medicine. 2020;382(1):41-50. DOI: 10.1056/NEJMoa1913662.

4. Solomon BJ, Bauer TM, Mok TSK, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. Journal of Clinical Oncology. 2024.

5. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer (DESTINY-Breast04). New England Journal of Medicine. 2022;387(1):9-20.

6. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: results of the NCI-MATCH trial Subprotocol H. Journal of Clinical Oncology. 2020;38(33):3895-3904.

7. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New England Journal of Medicine. 2018;378(8):731-739.

8. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI). Lancet Oncology. 2020;21(12):1630-1642.

9. Robert NJ, Nwokeji ED, Gao C, et al. Real-world biomarker testing and treatment patterns in patients with advanced non-small cell lung cancer. Lung Cancer. 2022.

10. Evangelist MC, Butrynski JE, et al. Molecular biomarker testing patterns in advanced NSCLC: MYLUNG Consortium. ASCO Annual Meeting. 2023.

11. Yorio JT, et al. Association of timely comprehensive genomic profiling with precision oncology treatment use and patient outcomes in advanced non-small cell lung cancer. JCO Precision Oncology. 2024. DOI: 10.1200/PO.23.00292.

12. Sunami K, Bando H, Yatabe Y, et al. Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors. Nature Medicine. 2026. DOI: 10.1038/s41591-025-04086-8.

13. Jin Q, et al. TrialGPT: matching patients to clinical trials with large language models. Nature Communications. 2024;15:9074. DOI: 10.1038/s41467-024-53081-z.

14. Haslem DS, Van Norman SB, Fulde G, et al. A retrospective analysis of precision medicine outcomes in patients with advanced cancer. Journal of Oncology Practice. 2017;13(2):e108-e119.

15. Haslem DS, Chakravarty I, Fulde G, et al. Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget. 2018;9(16):12316-12322.